Phase 2b Study of Oral Ezatiostat Hydrochloride (Telintra®) in Patients With Low to Intermediate-1 Risk, Non-Deletion 5q Myelodysplastic Syndrome
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Hematologic Improvement-Erythroid (HI-E) rate
Hematologic Improvement response will be assessed per the IWG MDS response criteria (2006)
At 8 weeks of treatment
No
Gail L Brown, MD
Study Director
Telik
United States: Food and Drug Administration
TLK199.2108
NCT01459159
October 2011
November 2014
Name | Location |
---|---|
University of Colorado | Denver, Colorado 80217 |
Columbia University | New York, New York 10032-3784 |
Vanderbilt University | Nashville, Tennessee 37232-6305 |
Bay Area Cancer Research Group | Concord, California 94520 |
The West Clinic | Memphis, Tennessee 38120 |
Center for Cancer and Blood Disorders | Bethesda, Maryland 20817 |
SIU School of Medicine, Simmons Cancer Institute | Springfield, Illinois 62794 |